Exelixis, Inc.
NASDAQ:EXELBiotechnology
+$0.34 today
- Market cap
- $17.17B
- Beta
- 0.43
- P/E (TTM)
- 16.3
- EPS (TTM)
- $3.23
Volume 1.82M
Average 2.55M
EXEL EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Exelixis, Inc.NASDAQ: EXEL
EBITDA · Q2 FY2026 · quarter ended Jul 2026
EBITDA grows, but more slowly than its trailing trend
Q2 FY2026 EBITDA of $269.66M rose 13.4% year over year, behind the +28.1% change in trailing-twelve-month EBITDA. Sequentially, it fell 1.8% from the prior quarter. Over 3 fiscal years it compounded at +53.4% a year.
Context
- EBITDA amounted to 39.7% of revenue in FY2025, up 6.6 pp from a year earlier.
- EBITDA increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 12 analysts of $1.36B (+47.8%) for the fiscal year ending Jan 2027, a step up from the +28.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJul 2026
- $269.66M-1.8% QoQ
- Last fiscal yearJan 2026
- $921.76M+28.2% YoY
- LTMJul 2026
- $1.05B+28.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +13.4% | +12.7% | -0.7 pp |
| 1 year | +28.2% | +47.8% | +19.6 pp |
| 3-year CAGR | +53.4% | +22.1% | -31.3 pp |
| 5-year CAGR | +19.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 921.76M USD
- Year-over-year change
- +28.2%
- 4-year CAGR
- +31.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2026-01-02 | 921.76M | +28.2% |
| FY2024 | 2025-01-03 | 718.75M | +153.8% |
| FY2023 | 2023-12-31 | 283.24M | +11.0% |
| FY2022 | 2022-12-31 | 255.23M | -17.1% |
| FY2021 | 2021-12-31 | 307.78M | — |
EBITDA vs competitors
How EXEL compares with its peers on the latest reported figures
- EXEL's LTM Jul 2026 EBITDA of $1.05B is the 4th highest of the 8 companies compared; the peer median is $131.28M.
- Its year-over-year change of +28.1% is the 5th highest of 7, against a peer median of +51.3%.
- EBITDA amounts to 43.0% of revenue for EXEL, versus a peer median of 35.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $21.37B | +18.6% | +29.7% | 34.4% | |
| LTM Jun 2026 | $2.07B | +52.6% | +43.2% | 35.5% | |
| LTM Jun 2026 | $1.22B | — | -43.3% | 29.5% | |
| LTM Jul 2026 | $1.05B | +28.1% | +53.4% | 43.0% | |
| LTM Mar 2026 | $131.28M | +170.9% | — | 43.8% | |
| LTM Jun 2025 | -$7.49M | +93.2% | — | 1.2% | |
| LTM Mar 2026 | -$162.5M | +50.0% | — | 74.8% | |
| LTM Jun 2026 | -$1.69B | -111.6% | — | — | |
| Peer median (excluding EXEL) | $131.28M | +51.3% | +29.7% | 35.0% | |
Competitors are the stored peer set for EXEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Jan 2025 | FY2025 Jan 2026 |
|---|---|---|---|---|---|
| Revenue | 1.43B | 1.61B | 1.83B | 2.17B | 2.32B |
| Cost of Revenue | 52.87M | 57.91M | 72.55M | 76.22M | 83.7M |
| Gross Profit | 1.38B | 1.55B | 1.76B | 2.09B | 2.24B |
| Gross Margin | 96.3% | 96.4% | 96.0% | 96.5% | 96.4% |
| Research & Development | 693.72M | 891.81M | 1.04B | 910.41M | 825M |
| Selling, General & Admin | 401.72M | 459.86M | 542.71M | 492.13M | 518.73M |
| Operating Expenses | 1.1B | 1.35B | 1.59B | 1.49B | 1.36B |
| Depreciation & Amortization | 13.63M | 20.88M | 25.72M | 28.8M | 29.06M |
| EBITDA | 307.78M | 255.23M | 283.24M | 718.75M | 921.76M |
| EBITDA Margin | 21.4% | 15.8% | 15.5% | 33.1% | 39.7% |
| Operating Income | 286.67M | 201.48M | 170.89M | 604.62M | 872.19M |
| Operating Margin | 20.0% | 12.5% | 9.3% | 27.9% | 37.6% |
| Interest Income | 7.67M | 33.07M | 86.54M | 77.16M | 69.21M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 7.49M | 32.87M | 86.64M | 77.02M | 69.02M |
| Income Before Tax | 294.15M | 234.35M | 257.52M | 681.64M | 941.21M |
| Pre-Tax Margin | 20.5% | 14.5% | 14.1% | 31.4% | 40.6% |
| Income Tax Expense | 63.09M | 52.07M | 49.76M | 160.37M | 158.64M |
| Net Income | 231.06M | 182.28M | 207.77M | 521.27M | 782.57M |
| Net Margin | 16.1% | 11.3% | 11.4% | 24.0% | 33.7% |
| EPS (Basic) | 0.73 | 0.57 | 0.65 | 1.80 | 2.88 |
| EPS (Diluted) | 0.72 | 0.56 | 0.65 | 1.76 | 2.78 |
| Weighted Avg Shares | 314.88M | 321.53M | 318.15M | 290.03M | 271.57M |
| Weighted Avg Shares (Diluted) | 322.36M | 324.56M | 321.46M | 296.13M | 281.86M |
Exelixis, Inc.
NASDAQ:EXEL
Intrinsic Alpha fair value
Locked
Current Price
$68.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.